IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 10% WITH PLACEBO IN THE TREATMENT OF RSA

免疫%20球蛋白%20静脉%20（人类）%2010%%20WITH%20PLACEBO%20IN%20THE%20TREATMENT%20OF%20RSA

• 批准号: 7375413
• 负责人: WILLIAM H KUTTEH
• 金额: $ 0.43万
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375413
• 关键词: IMMUNE; GLOBULIN; INTRAVENOUS; HUMAN; 10

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this clinical trial is to evaluate the efficacy of IVIG in improving the live birth rate in couples with unexplained recurrent spontaneous abortion (RSA). By evaluating the use of IVIG in this patient population, a greater understanding of the maternal immune response to pregnancy will be achieved.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本临床试验的目的是评估IVIG在提高不明原因复发性流产（RSA）夫妇活产率方面的疗效。通过评估IVIG在该患者人群中的使用，将更好地了解母体对妊娠的免疫反应。